REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg

Study Overview
=================
Brief Summary
-----------------
Retrospective analysis of treatment outcome and side effects of testicular cancer patients that had been diagnosed at the University Magdeburg from 1960 until 2012.

Detailed Description
-----------------
Creating an ACCESS Windows form based Data Registry for testicular cancer patients. Relevant data for testicular cancer patients based on EAU-guidelines 2013 and EORTC/RTOG, Lent-SOMA, CTC. All testicular cancer patients who had been histopathologically diagnosed al the Institute of Pathology at the University Magdeburg. About 2000 patients from 1960 until 2012. Postgraduate students collecting data requesting hospital documents, cancer registry of Sachsen-Anhalt, family practitioners and urologists as well as patients. Statistically Analysis with ACCESS and IBM SPSS statistics.

Official Title
-----------------
Retrospective Analysis of Testicular Cancer Patients With Histopathological Analysis or Urological Treatment at the University Magdeburg 1960-2012.

Conditions
-----------------
Testicular Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: testicular cancer histopathologically diagnosed at the University Magdeburg Germany Exclusion Criteria: none.
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Seminoma<br>Seminoma | |
| Non-Seminoma<br>Non-Seminoma | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) | Overall survival (OS). | Up to 52 years. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-specific survival. | Disease-specific survival of testicular cancer. | Up to 52 years. | 
| Chronic side effects of testicular-cancer-specific radiation therapies. | All Therapy Associated side effects of radiation therapy using EORTC (European Organisation for Research and Treatment of Cancer) /RTOG- (Radiation Therapy Oncology Group) - RTOG/EORTC Late Radiation Morbidity Scoring Schema), LENT-SOMA-(Late Effects of Normal Tissues)-, CTCAE-(Common Terminology Criteria for Adverse Events V4)-Scores. See | Up to 52 years. | 
| Chronic side effects of testicular-cancer-specific chemotherapies. | All Therapy Associated side effects of chemotherapy using CTCAE-(Common Terminology Criteria for Adverse Events V4)-Score. | Up to 52 years. | 
| Chronic side effects of testicular-cancer-specific surgical therapies. | All Therapy Associated side effects of surgical therapy using CTCAE-(Common Terminology Criteria for Adverse Events V4)-Score. | Up to 52 years. | 
| Secondary Malignoma | Assessment of Development of Secondary malignoma after diagnosis of testicular cancer; Secondary malignoma other than testicular cancer and metachronous Primary testicular cancer | Up to 52 years. | 
| Progressive-free survival (PFS). | Progressive-free survival (PFS). | Up to 52 years. | 
| Relapse-free survival (RLS). | Relapse-free survival (RLS). | Up to 52 years. | 
| Quality of Life (QoL). | Assessment of the current QoL using ECOG and EORTC-QLQ-C30-V3D. | Current situation. | 
| Cause of death. | Cause of death. | Up to 52 years. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Testicular cancer